跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/EUCTR2004-002017-37-IT
EUCTR2004-002017-37-IT进行中（未招募）不适用

Phase III randomized trial of concomitant radiation, cisplatin, and tirapazamine (SR259075) versus concomitant radiation and cisplatin in patients with advanced head and neck cancer.

SANOFI-SYNTHELABO0 个研究点开始时间: 2005年6月24日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症

试验速览

阶段
不适用
状态
进行中（未招募）
研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1.2 Adults (18-64 years) yes
  • •F.1.2.1 Number of subjects for this age range
  • •F.1.3 Elderly (>=65 years) yes
  • •F.1.3.1 Number of subjects for this age range

排除标准

  • 未提供

研究者

相似试验

进行中（未招募）
1 期
Phase III randomized trial of concomitant radiation, cisplatin, and tirapazamine (SR259075) versus concomitant radiation and cisplatin in patients with advanced head and neck cancer - TRACE
EUCTR2004-002017-37-ESSanofi-Synthelabo Research550
进行中（未招募）
不适用
Phase III randomized trial of concomitant radiation, cisplatin, and tirapazamine (SR259075) versus concomitant radiation and cisplatin in patients with advanced head and neck cancer - TRACE
EUCTR2004-002017-37-BESanofi-Synthelabo Research550
进行中（未招募）
不适用
Phase III randomized trial of concomitant radiation, cisplatin, and tirapazamine (SR259075) versus concomitant radiation and cisplatin in patients with advanced head and neck cancer - TRACE
EUCTR2004-002017-37-HUSanofi-Synthelabo Research550
进行中（未招募）
不适用
Phase III randomized trial of concomitant radiation, cisplatin, and tirapazamine (SR259075) versus concomitant radiation and cisplatin in patients with advanced head and neck cancer - TRACEOncology: Advanced Head and Neck cancerMedDRA version: 7.0Level: LLTClassification code 10025960
EUCTR2004-002017-37-DESanofi-Synthelabo Research550
进行中（未招募）
1 期
a research study to compare the standard treatment and the study drug (degarelix) in combination with radiotherapy in patients with high-risk localized or locally-advanced cancer, who receive this treatment after initial radical prostatectomy or as primary therapy.very high risk localized or locally advanced prostate cancerMedDRA version: 20.0 Level: PT Classification code 10060862 Term: Prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2015-005098-19-GBEuropean Organisation for Research and Treatment of Cancer (EORTC)885